Authors Reply to Letter to the Editor- In Response to: Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation"

Khayyam Durrani¹, John H Kempen^{2

3

4}, C Stephen Foster^{3

5

6}; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group

Affiliations

¹ a Division of Ophthalmology , University of Connecticut Health , Farmington , Connecticut , USA.
² b Department of Ophthalmology , Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA.
³ c Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
⁴ d Discovery Eye Center , MyungSung Christian Medical Center and MyungSung Medical School , Addis Ababa , Ethiopia.
⁵ e Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.
⁶ f Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.

Comment

Khayyam Durrani et al. Ocul Immunol Inflamm. 2019.

. 2019;27(1):71.

doi: 10.1080/09273948.2017.1379545. Epub 2017 Oct 18.

Khayyam Durrani¹, John H Kempen^{2

3

4}, C Stephen Foster^{3

5

6}; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group

¹ a Division of Ophthalmology , University of Connecticut Health , Farmington , Connecticut , USA.
² b Department of Ophthalmology , Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA.
³ c Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
⁴ d Discovery Eye Center , MyungSung Christian Medical Center and MyungSung Medical School , Addis Ababa , Ethiopia.
⁵ e Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.
⁶ f Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.

No abstract available

Comment on

Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation".
Ghembaza MEA, Lounici A. Ghembaza MEA, et al. Ocul Immunol Inflamm. 2019;27(1):70. doi: 10.1080/09273948.2017.1371312. Epub 2017 Oct 11. Ocul Immunol Inflamm. 2019. PMID: 29020494 No abstract available.